Effectiveness of Fecal Microbiota Transplantation for Weight Loss in Patients With Obesity Undergoing Bariatric Surgery: A Randomized Clinical Trial.

Importance: Severe obesity is a major health concern. However, a few patients remain resistant to bariatric surgery and other treatments. Animal studies suggest that weight may be altered by fecal microbiota transplantation (FMT) from a lean donor.

Open vs. laparoscopic surgery for rectal prolapse: a case-controlled study assessing short-term outcome.

Purpose: This study was undertaken to evaluate the efficacy and safety of laparoscopic repair for rectal prolapse.

Methods: A case-control study was undertaken. The case group consisted of a consecutive series of patients who underwent laparoscopic repair for rectal prolapse between February 1993 and June 2000.

Antireflux surgery enhances gastric emptying.

Objective: To evaluate the influence of antireflux surgery on gastric emptying.

Design: Nonrandomized controlled trial 3 months before and after surgical intervention.

Setting: Secondary and tertiary referral center.

Complications of open and laparoscopic antireflux surgery: 32-year audit at a teaching hospital.

Background: Open or laparoscopic surgery for gastroesophageal reflux disease gives longterm freedom from symptoms in 83-100% of cases but has a certain percentage of complications. This study was undertaken to evaluate the early and late complication rates after primary or repeat antireflux operations.

Study Design: The records of all patients who underwent surgery for gastroesophageal reflux disease during a 32-year period at a university teaching hospital were reviewed retrospectively.

Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.

Background: Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically. As GERD is often a chronic condition, we compared the long-term costs of medical and surgical management.

Methods: The medical regimens were ranitidine (150 or 300 mg/day), omeprazole (20 or 40 mg/day), and lansoprazole (30 mg/day), with costs calculated for total life expectancy after diagnosis and for one-third of that time.